Pharvaris Aims for Key Data Readouts and NDA Submission in 2026
Event summary
- Pharvaris anticipates topline data from the CHAPTER-3 Phase 3 study of deucrictibant XR for HAE prophylaxis in 3Q2026.
- NDA submission for deucrictibant IR for on-demand HAE treatment remains on track for 1H2026.
- CREAATE Phase 3 study for AAE-C1INH is ongoing with enrollment progressing as planned.
- Pharvaris closed a $132 million underwritten offering, extending cash runway into 2028.
The big picture
Pharvaris is advancing its pipeline of bradykinin B2 receptor antagonists, aiming to address unmet needs in hereditary and acquired angioedema. The company's strategic focus on both prophylactic and on-demand treatments positions it to compete in a niche but growing market for oral therapies. The recent funding round and upcoming regulatory milestones underscore the company's push towards commercialization, though execution risks remain.
What we're watching
- Regulatory Milestones
- The timing and outcome of the NDA submission for deucrictibant IR in 1H2026 will be critical for Pharvaris' commercialization strategy.
- Clinical Data Impact
- The topline data from the CHAPTER-3 study in 3Q2026 will determine the efficacy and safety profile of deucrictibant XR, influencing its market potential.
- Cash Runway Management
- The $132 million offering extends the cash runway into 2028, but the pace of R&D and commercialization expenses will dictate the actual duration.
Related topics